DrugGen 2: A disease-aware language model for enhancing drug discovery

• URL: http://arxiv.org/abs/2607.08404v1
• Date: Thu, 09 Jul 2026 12:29:33 GMT
• Title: DrugGen 2: A disease-aware language model for enhancing drug discovery
• Abstract summary: DrugGen-2 is a novel generative model that generates molecules conditioned on disease and target sequences.<n>DrugGen-2 was developed by fine-tuning a pre-trained GPT-2 model on a curated dataset of approved drugs linked to their diseases and targets.<n>When evaluated on five protein targets relevant to diabetic nephropathy, DrugGen-2 significantly outperformed baseline models.
• Score: 0.0
• License: http://creativecommons.org/licenses/by-nc-nd/4.0/
• Abstract: Current computational approaches for drug design typically focus on generating molecules conditioned on specific targets or general molecular properties, often neglecting the influence of disease context on target behavior and therapeutic outcomes. To address this gap, we introduce DrugGen-2, a novel generative model that designs small molecules conditioned on both disease ontology and target protein sequences. DrugGen-2 was developed by fine-tuning a pre-trained GPT-2 model on a curated dataset of approved drugs linked to their diseases and targets, using a two-step strategy of supervised fine-tuning followed by reinforcement learning via group relative policy optimization (GRPO). This process was guided by reward functions optimizing for chemical validity, novelty, diversity, and high predicted binding affinity. When evaluated on five protein targets relevant to diabetic nephropathy, DrugGen-2 significantly outperformed baseline models (DrugGPT and DrugGen). It demonstrated a superior capacity to generate unique molecules, exhibited greater structural similarity to approved drugs, and achieved improved predicted binding affinities across all targets. Molecular docking analyses further supported these findings, identifying candidate ligands with strong binding potential, including compounds with predicted affinities (-9.917, -9.485, and -9.367) exceeding those of reference drugs such as enalapril for angiotensin-converting enzyme (-8.283). By integrating disease-specific context into molecular generation, DrugGen-2 advances AI-assisted drug discovery, offering a powerful tool for de novo design and drug repurposing that accounts for the complex interplay between diseases and molecular targets.

Related papers

• Transcriptome-Conditioned Personalized De Novo Drug Generation for AML Using Metaheuristic Assembly and Target-Driven Filtering [0.0]
  Acute Myeloid Leukemia (AML) remains a clinical challenge due to its extreme molecular heterogeneity and high relapse rates.<n>This paper presents a novel, end-to-end computational framework that bridges the gap between patient-specific transcriptomics and de novo drug discovery.
  arXiv  Detail & Related papers  (2025-12-24T17:39:37Z)
• DrugImproverGPT: A Large Language Model for Drug Optimization with Fine-Tuning via Structured Policy Optimization [53.27954325490941]
  Finetuning a Large Language Model (LLM) is crucial for generating results towards specific objectives.<n>This research introduces a novel reinforcement learning algorithm to finetune a drug optimization LLM-based generative model.
  arXiv  Detail & Related papers  (2025-02-11T04:00:21Z)
• DrugGen: Advancing Drug Discovery with Large Language Models and Reinforcement Learning Feedback [0.0]
  DrugGen is an enhanced model based on the DrugGPT structure. It is fine-tuned on approved drug-target interactions and optimized with proximal policy optimization. By producing high-quality small molecules, DrugGen provides a high-performance medium for advancing pharmaceutical research and drug discovery.
  arXiv  Detail & Related papers  (2024-11-20T01:21:07Z)
• Aligning Target-Aware Molecule Diffusion Models with Exact Energy Optimization [147.7899503829411]
  AliDiff is a novel framework to align pretrained target diffusion models with preferred functional properties. It can generate molecules with state-of-the-art binding energies with up to -7.07 Avg. Vina Score.
  arXiv  Detail & Related papers  (2024-07-01T06:10:29Z)
• TAGMol: Target-Aware Gradient-guided Molecule Generation [19.977071499171903]
  3D generative models have shown significant promise in structure-based drug design (SBDD) We decouple the problem into molecular generation and property prediction. The latter synergistically guides the diffusion sampling process, facilitating guided diffusion and resulting in the creation of meaningful molecules with the desired properties. We call this guided molecular generation process as TAGMol.
  arXiv  Detail & Related papers  (2024-06-03T14:43:54Z)
• A Cross-Field Fusion Strategy for Drug-Target Interaction Prediction [85.2792480737546]
  Existing methods fail to utilize global protein information during DTI prediction. Cross-field information fusion strategy is employed to acquire local and global protein information. Siamese drug-target interaction SiamDTI prediction method achieves higher accuracy levels than other state-of-the-art (SOTA) methods on novel drugs and targets.
  arXiv  Detail & Related papers  (2024-05-23T13:25:20Z)
• drGT: Attention-Guided Gene Assessment of Drug Response Utilizing a Drug-Cell-Gene Heterogeneous Network [8.664433151000255]
  drGT is a graph deep learning model that predicts sensitivity and aids in biomarker identification using attention coefficients (ACs)<n>The model is trained and evaluated using major benchmark datasets: Sanger GDSC, NCI60, and Broad CTRP, which cover a wide range of drugs and cancer cell lines.
  arXiv  Detail & Related papers  (2024-05-14T22:16:52Z)
• Tailoring Molecules for Protein Pockets: a Transformer-based Generative Solution for Structured-based Drug Design [133.1268990638971]
  De novo drug design based on the structure of a target protein can provide novel drug candidates. We present a generative solution named TamGent that can directly generate candidate drugs from scratch for a given target.
  arXiv  Detail & Related papers  (2022-08-30T09:32:39Z)
• Improved Drug-target Interaction Prediction with Intermolecular Graph Transformer [98.8319016075089]
  We propose a novel approach to model intermolecular information with a three-way Transformer-based architecture. Intermolecular Graph Transformer (IGT) outperforms state-of-the-art approaches by 9.1% and 20.5% over the second best for binding activity and binding pose prediction respectively. IGT exhibits promising drug screening ability against SARS-CoV-2 by identifying 83.1% active drugs that have been validated by wet-lab experiments with near-native predicted binding poses.
  arXiv  Detail & Related papers  (2021-10-14T13:28:02Z)
• Benchmarking Deep Graph Generative Models for Optimizing New Drug Molecules for COVID-19 [11.853524110656991]
  Design of new drug compounds with target properties is a key area of research in generative modeling. We present a small drug molecule design pipeline based on graph-generative models and a comparison study of two state-of-the-art graph generative models for designing COVID-19 targeted drug candidates.
  arXiv  Detail & Related papers  (2021-02-09T17:49:26Z)
• CogMol: Target-Specific and Selective Drug Design for COVID-19 Using Deep Generative Models [74.58583689523999]
  We propose an end-to-end framework, named CogMol, for designing new drug-like small molecules targeting novel viral proteins. CogMol combines adaptive pre-training of a molecular SMILES Variational Autoencoder (VAE) and an efficient multi-attribute controlled sampling scheme. CogMol handles multi-constraint design of synthesizable, low-toxic, drug-like molecules with high target specificity and selectivity.
  arXiv  Detail & Related papers  (2020-04-02T18:17:20Z)

This list is automatically generated from the titles and abstracts of the papers in this site.

This site does not guarantee the quality of this site (including all information) and is not responsible for any consequences.